Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition

Journal of Oral Pathology and Medicine

Volumn 41, Issue 9, 2012, Pages 713-720

  Patntirapong, Somying ^a   Singhatanadgit, Weerachai ^a   Chanruangvanit, Chatvadee ^a   Lavanrattanakul, Kwankamol ^a   Satravaha, Yodhathai ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Cytotoxicity; MC3T3 E1; Mesenchymal stem cell; Mineralization; Osteoblast differentiation; Zoledronic acid

Indexed keywords

ANNEXIN; MESSENGER RNA; ZOLEDRONIC ACID;

ANIMAL CELL; ARTICLE; BIOMINERALIZATION; BONE DEVELOPMENT; BONE MINERALIZATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRUCTURE; CELL TYPE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; JAW DISEASE; MESENCHYME CELL; MORPHOLOGY; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STAINING;

EID: 85027938120     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01154.x     Document Type: Article

References (32)

1. Brandi ML. Current treatment approaches for Paget's Disease of Bone. Discov Med 2010; 10: 209-12.
2. Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest 2010; 28: 944-57.
3. Mahtani R, Jahanzeb M. Bisphosphonates as anticancer therapy for early breast cancer. Clin Breast Cancer 2010; 10: 359-66.
4. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88(12 Suppl): 2961-78.
5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
6. Landesberg R, Wilson T, Grbic JT. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series. Dent Today 2006; 25: 52, 54-7.
7. Pozzi S, Marcheselli R, Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48: 56-64.
8. Nastro E, Musolino C, Allegra A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 2007; 117: 181-7.
9. Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007; 15: 197-202.
10. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope 2007; 117: 30-4.
11. Huja SS, Fernandez SA, Phillips C, Li Y. Zoledronic acid decreases bone formation without causing osteocyte death in mice. Arch Oral Biol 2009; 54: 851-6.
12. Pozzi S, Vallet S, Mukherjee S, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009; 15: 5829-39.
13. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 1999; 14: 893-903.
14. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res 2002; 17: 101-10.
15. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
16. Chaudhary LR, Hofmeister AM, Hruska KA. Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone 2004; 34: 402-11.
17. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37.
18. Peter B, Zambelli PY, Guicheux J, Pioletti DP. The effect of bisphosphonates and titanium particles on osteoblasts: an in vitro study. J Bone Joint Surg Br 2005; 87: 1157-63.
19. Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009; 106: 109-18.
20. Kobayashi Y, Hiraga T, Ueda A, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 2010; 28: 165-75.
21. Schindeler A, Little DG. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 2005; 338: 710-6.
22. Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008; 23: 6-16.
23. Peter B, Pioletti DP, Laib S, et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 2005; 36: 52-60.
24. Ebert R, Zeck S, Krug R, et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 2009; 44: 858-64.
25. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105.
26. Vaisman DN, McCarthy AD, Cortizo AM. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biol Trace Elem Res 2005; 104: 131-40.
27. Scheper MA, Badros A, Salama AR, et al. A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer 2009; 17: 1553-7.
28. Kikuiri T, Kim I, Yamaza T, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 2010; 25: 1668-79.
29. Wennberg C, Hessle L, Lundberg P, et al. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res 2000; 15: 1879-88.
30. Anderson HC. Mechanism of mineral formation in bone. Lab Invest 1989; 60: 320-30.
31. Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep 2003; 5: 222-6.
32. Koch FP, Yekta SS, Merkel C, Ziebart T, Smeets R. The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro. Head Face Med. 2010; 6: 12.